Prognostic and Clinicopathological Significance of CCAT2 in Chinese Patients with Various Tumors

Tian, Guangwei; Li, Nan

doi:10.5301/ijbm.5000281

Cited by 5 publications

(9 citation statements)

References 32 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Compared to previous meta-analyses, our research has several advantages [ 13 – 15 ]. First of all, the included studies and cases extended from 11 studies with 1335 cases [ 13 ] to 20 studies and TCGA database with 13285 cases. Moreover, we performed several subgroup analyses to further explore the role of CCAT2 in different types of tumors and also achieved a significant correlation between high CCAT2 expression and worse OS in survival curve studies.…”

Section: Discussionmentioning

confidence: 99%

“…The search strategy combining the terms “CCAT2” or “colon cancer associated transcript 2” is based on the purpose of the study. We also reviewed comments and references related to CCAT2 by other methods, including the extraction of previous articles cited in the meta-analysis of CCAT2 [ 13 – 15 ]. The deadline for our project was on December 29, 2019.…”

Section: Methodsmentioning

confidence: 99%

“…The above evidence indicates that CCAT2 is involved in tumor progression. Moreover, some previous meta-analyses have reported that increased CCAT2 expression is significantly associated with lymph node metastasis, distant metastasis, and higher clinical stage [ 13 , 14 ]. However, sample quantity is limited, and the relevance of CCAT2 to other clinicopathological parameters has not been adequately studied in these studies.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A Comprehensive Exploration of the lncRNA CCAT2: A Pan-Cancer Analysis Based on 33 Cancer Types and 13285 Cases

Huang

Guan

et al. 2020

Disease Markers

View full text Add to dashboard Cite

Whether the lncRNA CCAT2 expression level affects the clinical progression and outcome of cancer patients has not yet been fully elucidated. There is still an inconsistent view regarding the correlation between CCAT2 expression and clinicopathological factors, including survival data. Besides, the regulation mechanism of CCAT2 in human cancer is still unclear. Our study analyzed a large number of publication data and TCGA databases to identify the association of CCAT2 expression with clinicopathological factors and to explore the regulatory mechanisms in human cancers. We designed a comprehensive study to determine the expression of CCAT2 in human cancer by designing a meta-analysis of 20 selected studies and the TCGA database, using StataSE 12.0 to explore the relationship between CCAT2 expression and both the prognosis and clinicopathological features of 33 cancer types and 13285 tumor patients. Moreover, we performed GO and KEGG pathway enrichment analyses on potential target genes of CCAT2 collected from GEPIA and LncRNA2Target V2.0. The level of CCAT2 expression in tumor tissues is higher than that in paired normal tissues and is significantly associated with a poor prognosis in cancer patients. Besides, overexpression of CCAT2 was significantly associated with tumor size, clinical stage, and TNM classification. Meanwhile, CCAT2 expression is the highest in stage II of human cancer, followed by stage III. Finally, 111 validated target gene symbols were identified, and GO and KEGG demonstrated that the CCAT2 validation target was significantly enriched in several pathways, including microRNAs in the cancer pathway. In summary, CCAT2 can be a potential biomarker associated with the progression and prognosis of human cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Comprehensive Exploration of the lncRNA CCAT2: A Pan-Cancer Analysis Based on 33 Cancer Types and 13285 Cases

Huang

Guan

et al. 2020

Disease Markers

View full text Add to dashboard Cite

show abstract

“…LncRNAs are widely reported to regulate gene expression at epigenetic, transcriptional, and posttranscriptional levels [8–10] and aberrant expression of lncRNAs can be involved in cancer initiation, progression, and metastasis [11–13]. Furthermore, increasing evidences suggested that lncRNAs could serve as potential biomarkers with high sensitivity and specificity in cancer detection and diagnosis [14–17].…”

Section: Introductionmentioning

confidence: 99%

Potential Role of lncRNA H19 as a Cancer Biomarker in Human Cancers Detection and Diagnosis: A Pooled Analysis Based on 1585 Subjects

Liu

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) have been reported to serve as diagnostic and prognostic biomarkers of cancers, which play vital roles in tumorigenesis and tumor progression. Several studies have been performed to explore diagnostic value of lncRNA H19 in cancer detection and diagnosis. However, there are still inconsistent results in diagnostic accuracy and reliability in individual studies. Therefore, the present study was performed to summarize the overall diagnostic performance of lncRNA H19 in cancer detection and diagnosis. A total of eight studies with 770 cases and 815 controls were included in this pooled analysis. The pooled diagnostic results were as follows: sensitivity, 0.69 (95%CI=0.62-0.76), specificity, 0.79 (95% CI=0.70-0.86), positive likelihood ratio (PLR), 3.31 (95%CI=2.29-4.78), negative likelihood (NLR), 0.39 (95%CI=0.31-0.49), diagnostic odds ratio (DOR), 8.53 (95%CI=4.99-14.60), and area under the curve (AUC), 0.79 (95%CI=0.76-0.83). Deeks’ funnel plot asymmetry test (P=0.13) suggested no potential publication bias. Our results indicated that lncRNA H19 had a relatively moderate accuracy in cancer detection and diagnosis. Further comprehensive prospective studies with large sample sizes are urgently required to validate our findings.

show abstract

Long non-coding RNA colon cancer-associated transcript 2: role and function in human cancers

Wang

Zhang

et al. 2023

Chinese Medical Journal

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are a family of non-protein-coding RNAs that span a length of over 200 nucleotides. Research reports have illustrated that lncRNAs are involved in various cellular processes and that their abnormal expression leads to the occurrence and development of various tumors. Colon cancer-associated transcript 2 (CCAT2) was first reported as an oncogene in colon cancer. LncRNA CCAT2 is abnormally expressed in hepatocellular carcinoma, cholangiocarcinoma, lung cancer, breast cancer, ovarian cancer, glioma, and other tumors. In tumor tissues, abnormally overexpressed CCAT2 can affect cell proliferation, migration, epithelial-mesenchymal transition, apoptosis, and other biological behaviors through endogenous RNAs mechanisms, various signaling pathways, transcriptional regulation, and other complex mechanisms. Additionally, the overexpression of CCAT2 is also closely related to the tumor size, tumor node metastasis (TNM) stage, survival time, and other prognostic factors, suggesting that it is a potential prognostic indicator. This article reviews the biological functions of CCAT2 and its mechanisms of action in tumors from previous studies. In this review, we attempt to provide a molecular basis for future clinical applications of lncRNA CCAT2.

show abstract

Prognostic and Clinicopathological Significance of CCAT2 in Chinese Patients with Various Tumors

Abstract: These results indicate that CCAT2 is a biomarker to predict tumor progression and a potential prognostic marker in multiple cancers. Additional well-designed clinical studies are needed to validate these findings.

Cited by 5 publications

References 32 publications

A Comprehensive Exploration of the lncRNA CCAT2: A Pan-Cancer Analysis Based on 33 Cancer Types and 13285 Cases

A Comprehensive Exploration of the lncRNA CCAT2: A Pan-Cancer Analysis Based on 33 Cancer Types and 13285 Cases

Potential Role of lncRNA H19 as a Cancer Biomarker in Human Cancers Detection and Diagnosis: A Pooled Analysis Based on 1585 Subjects

Long non-coding RNA colon cancer-associated transcript 2: role and function in human cancers

Contact Info

Product

Resources

About